体重指数对心脏植入式电子设备手术并发症的影响

相关实验视频

Updated: Jun 19, 2026

23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

Tuncay Güzel¹, Muhammed Demir², Adem Aktan³

¹Department of Cardiology, Health Science University, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey.

Pacing and clinical electrophysiology : PACE

|December 11, 2023

概括

较高的体重指数 (BMI) 会增加心脏植入式电子设备 (CIED) 程序后并发症的风险. 肥胖患者患有更多的血液瘤和肺胸瘤,突出显示BMI是CIED结果的关键因素.

科学领域:

心脏病学心脏病学
医疗器械医疗器械
公共卫生公共卫生

背景情况:

心脏植入式电子设备 (CIED) 程序具有固有的并发症风险.
调查可修改的风险因素,如体重指数 (BMI),对于提高患者安全至关重要.

研究的目的:

确定身体质量指数 (BMI) 与接受CIED手术的患者周围手术并发症的发生率之间的关联.
为了确定特定的并发症,这些并发症在具有较高BMI的个体中更为普遍.

主要方法:

一项回顾性研究包括1676名接受CIED各种手术的患者.
患者被分为非肥胖 (BMI < 25 kg/m2),超重 (25 ≤ BMI < 30 kg/m2) 和肥胖 (BMI ≥ 30 kg/m2) 的组.
主要终点是临床显著的血液瘤,心周溢出/栓塞,肺胸和感染的复合.

主要成果:

累积并发症率在肥胖组 (8.9%) 与超重 (4.3%) 和非肥胖 (3.0%) 组相比显著更高 (p=0.001).
肥胖患者的临床显著性血液瘤 (1.9%) 和肺胸部 (3.3%) 发生率显著更高.
多变量分析确定BMI (OR:1.069,p=0.01),性别和高血压作为累积事件的独立预测因素.

结论:

在接受CIED手术的BMI较高的患者中,周围手术并发症,特别是血瘤和肺胸,更为频繁.
升高的BMI是CIED植入后不良事件的独立预测指标.
对肥胖患者的风险分层和潜在的程序修改可能是有必要的,以减少并发症的发生率.

关键词:

身体质量指数 (BMI) 是什么?心血管植入式电子设备是什么这是一个复杂的并发症.这是一个心脏起器.

相关概念视频

01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...

01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...